Combination of thiazide diuretics and angiotensin receptor blockers attenuates osteoporosis in hypertensive rats

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2010, Pages 115-122

  Shimizu, Hideo ^a   Nakagami, Hironori ^b   Yasumasa, Natsuki ^a,b   Osako, Mariana Kiomy ^a   Shimamura, Munehisa ^b   Miyake, Takeshi ^b   Nakagami, Futoshi ^a,b   Koriyama, Hiroshi ^b   Rakugi, Hiromi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Angiotensin type 1 receptor blocker; Bone; Osteoporosis; Thiazide diuretics

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; DEOXYPYRIDINOLINE; HYDROCHLOROTHIAZIDE; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BONE DENSITY; BONE METABOLISM; CELL ACTIVATION; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME ACTIVITY; ESTROGEN DEFICIENCY; METABOLIC PARAMETERS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TIBIA;

EID: 78649234735     PISSN: 18715222     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152210793292588     Document Type: Article

References (25)

1. Cappuccio, F.P.; Meilahn, E; Zmuda, J.M.; Cauley, J.A. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet, 1999, 354(18), 971-975.
2. Tsuda, K.; Nishio, I.; Masuyama, Y. Bone mineral density in women with essential hypertension. Am. J. Hypertens., 2001, 14, 704-707.
3. McCarron, D.A.; Low serum concentrations of ionized calcium in patients with hypertension. N. Engl. J. Med., 1982, 307(4), 226-228.
4. McCarron, D.A.; Pingree, P.A.; Rubin, R.J.; Gaucher, S.M.; Mo-litch, M.; Krutzik, S. Enhanced parathyroid function in essential hypertension. A homeostatic response to a urinary calcium leak. Hypertension, 1980, 2(2), 162-168.
5. Rejnmark, L.; Vestergaard, P.; Mosekilde, L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J. Hypertens., 2006, 24(3), 581-589.
6. Vestergaard, P.; Rejnmark, L.; Mosekilde, L. Hypertension is a risk factor for fractures. Calcif. Tissue Int., 2009, 84(2), 103-111.
7. Wasnich, R.D.; Benfante, R.J.; Yano, K.; Heilbrun, L.; Vogel, J.M. Thiazide effect on the mineral content of bone. N. Engl. J. Med., 1983, 309(6), 344-347.
8. Store, R.M.; Smith, L.H.; Wilson, D.M.; Dube, W.J.; Goldsmith, R.S.; Arnaud, C.D. Hydrochlorothiazide effects on serum calcium and immunoreactive parathyroid hormone concentrations. Ann. Intern. Med., 1972, 77(4), 587-591.
9. LaCroix, A.Z.; Ott, S.M.; Ichikawa, L.; Scholes, D.; Barlow, W.E. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, pla-cebo-controlled trial. Ann. Intern. Med., 2000, 133(7), 516-526.
10. Hall, T.J.; Schaueblin, M. Hydrochlorothiazide inhibits osteoclastic bone resorption in vitro. Calcif. Tissue Int., 1994, 55(4), 266-268.
11. Shimizu, H.; Nakagami, H.; Osako, M.K.; Hanayama, R.; Kunugiza, Y.; Kizawa, T.;, Tomita, T.; Yoshikawa, H.; Ogihara, T.; Morishita, R. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J., 2008, 22(7), 2465-2475.
12. Shimizu, H.; Nakagami, H.; Osako, M.K.; Nakagami, F.; Kunugiza, Y.: Tomita, T.; Yoshikawa, H.; Rakugi, H.; Ogihara, T.; Morishita, R. Prevention of osteoporosis by angiotensin - converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens. Res., 2009, 32(9), 786-790.
13. Shimizu, H.; Nakagami, H.; Tsukamoto, I.; Morita, S.; Kunugiza, Y.; Tomita, T.; Yoshikawa, H.: Kaneda, Y.; Ogihara, T.; Morishita, R. NFkappaB decoy oligodeoxynucleotides ameliorates osteoporo-sis through inhibition of activation and differentiation of osteo-clasts. Gene Ther., 2006, 13(12), 933-941.
14. Ikeda, I.; Iinuma, K.; Takai, M.; Yanagawa, Y.; Kurata, K.; Ogihara, T.; Kumahara, Y. Measurement of plasma renin activity by a simple solid phase radioimmunoassay. J. Clin. Endocrinol. Metab., 1982, 54(2), 423-428.
15. Perez-Castrillon, J.L.; Justo, I.; Silva, J.; Sanz, A.; Igea, R.; Escudero, P.; Pueyo, C.; Diaz, C.; Hernández, G.; Dueñas, A. Bone mass and bone modelling markers in hypertensive postmenopausal women. J. Hum. Hypertens., 2003, 17(2), 107-110.
16. Wiens, M.; Etminan, M.; Gill, S.S.; Takkouche, B. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J. Intern. Med., 2006, 260(4), 350-362.
17. Asaba, Y.; Ito, M.; Fumoto, T.; Watanabe, K.; Fukuhara, R.; Takeshita, S.; Nimura, Y.; Ishida, J.; Fukamizu, A.; Ikeda, K. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J. Bone Miner. Res., 2009, 24(2), 241-250.
18. Grant, F.D.; Mandel, S.J.; Brown, E.M.; Williams, G.H.; Seely, E.W. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J. Clin. Endocrinol. Metab., 1992, 75(4), 988-992.
19. Perez-Castrillon, J.L.; Silva, J.; Justo, I.; Sanz, A.; Martin-Luquero, M.; Igea, R.; Escudero, P.; Pueyo, C.; Diaz, C.; Hernandez, G.; Dueñas, A. Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am. J. Hypertens., 2003, 16(6), 453-459.
20. Chrysant, S.G. Antihypertensive effectiveness of low-dose lisino-pril -hydrochlorothiazide combination. A large multicenter study [Lisinopril -Hydrochlorothiazide group]. Arch. Intern. Med., 1994, 154(7), 737-743.
21. Gradman, A.H.; Acevedo, C. Evolving strategies for the use of combination therapy in hypertension. Curr. Hypertens. Rep., 2002, 4(5), 343-349.
22. Wellington, K.; Faulds, D.M. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs, 2002, 62(13), 1983-2005.
23. Pool, J.L.; Glazer, R.; Weinberger, M.; Alvarado, R.; Huang, J.; Graff, A. Comparison of valsartan/ hydrochlorothiazide combination therapy at doses up to 320/25mg versus monotherapy: a double-blind, placebocontrolled study followed by long-term combination therapy in hypertensive adults. Clin. Ther., 2007, 29(1), 61-73.
24. Ofili, E.O. Dispelling the myth of 'aggressive' antihypertensive therapy. J. Clin. Hypertens. (Greenwich), 2006, 8(1Suppl. 1), 4-11.
25. Sica, D.A. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs, 2002, 62(3), 443-462.